Company intelligence / Profile preview
Merz
Frankfurt am Main, Germanymerz.com ↗
- Ownership
- Private
- Employees
- ~3730
- Development stage
- Commercial
01
Overview
Merz is a global leader in aesthetic medicine and neurotoxin therapy with a strong presence in therapeutic neurology. Its key innovations include the development of memantine for Alzheimer’s disease and next-generation botulinum toxin therapies. The company has an extensive commercial portfolio across more than 70 countries with significant U.S. market share.
- Therapeutic areas
- DermatologyNeurology
- Modalities
- Small moleculeBiologicTopical gelVitaminsOTC products
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Forest LaboratoriesLundbeck
Beyond the preview
Go deeper on Merz.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Merz.